KR20170067466A - Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract - Google Patents
Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract Download PDFInfo
- Publication number
- KR20170067466A KR20170067466A KR1020150174170A KR20150174170A KR20170067466A KR 20170067466 A KR20170067466 A KR 20170067466A KR 1020150174170 A KR1020150174170 A KR 1020150174170A KR 20150174170 A KR20150174170 A KR 20150174170A KR 20170067466 A KR20170067466 A KR 20170067466A
- Authority
- KR
- South Korea
- Prior art keywords
- spirulina
- extract
- present
- spirulina extract
- cognitive function
- Prior art date
Links
- 235000003724 spirulina extract Nutrition 0.000 title claims abstract description 58
- 206010012289 Dementia Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims description 16
- 230000003930 cognitive ability Effects 0.000 title description 2
- 230000003920 cognitive function Effects 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 240000002900 Arthrospira platensis Species 0.000 claims description 28
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 27
- 229940082787 spirulina Drugs 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 241000620196 Arthrospira maxima Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 13
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 10
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- 229960003530 donepezil Drugs 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241001464430 Cyanobacterium Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- -1 ribastigreen Chemical compound 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
Abstract
The present invention relates to a pharmaceutical composition for improving dementia or cognitive function comprising Spirulina extract as an active ingredient. The Spirulina extract of the present invention has excellent antioxidative activity, has a cognitive function improving effect, And since there is no side effect in the body due to its low toxicity as a natural ingredient, there is an effect that it can be effectively used for the production of new medicines and health functional foods for dementia or cognitive function improvement and treatment.
Description
The present invention relates to a composition for improving or treating dementia or cognitive function comprising Spirulina extract as an active ingredient.
Korea is rapidly becoming one of the fastest growing countries in the world. The per capita amount of geriatric diseases caused by this rapid aging society in Korea is steadily increasing. Among them, the average life expectancy is increasing each year, and the number of patients with degenerative brain disease such as dementia is increasing. In the aging society, degenerative brain diseases will cause serious national, social and economic burden beyond health care problems. have.
However, the cause of the degenerative brain disease such as senile dementia has not been elucidated yet. However, recently, it has been reported that the pathogenesis is caused by the death of neuronal cells due to oxidative stress, senile speckles of amyloid beta protein accumulation of neurofibrillary tangles composed of senile plaque and hyperphosphorylated tau protein and reduction of acetylcholine (Ach), a neurotransmitter by acetylcholinesterase (AchE) .
The main drugs for these symptoms are cholinesterase inhibitors (tacrine, aricept, donepezil, ribastigreen, galantamine) and NMDA-glutamate receptor antagonists (memantine). However, these drugs are not completely cured, but rather are neurotransmitter modalities for improving cognitive function, while they show temporary symptomatic improvement, while side effects such as hepatotoxicity, gastrointestinal disorders, cardiac arrest, weight loss and insomnia, And it is required to develop new therapeutic agents to overcome these existing problems.
On the other hand, natural medicine researches on cognitive impairment of the elderly are reported to be beneficial compared with chemical medicines due to the nature of natural products, and it is evaluated that it is effective for cognitive disorders. In addition, safety and efficacy have been proven in accordance with the direction of the existing research, so there is an advantage that the side effect is small and the development period and cost can be reduced.
However, it still has excellent therapeutic efficacy and has not been developed as a safely natural therapeutic agent in the body. Therefore, it is necessary to develop a new therapeutic agent derived from natural materials to improve dementia and cognitive function.
Accordingly, the present invention confirms a new use of Spirulina extract having excellent dementia or cognitive function improving effect without side effects such as hepatotoxicity, gastrointestinal disorder, cardiac arrest, weight loss and insomnia, which are generated in the conventional cognitive function improving agent.
Accordingly, it is an object of the present invention to provide a pharmaceutical composition for improving dementia or cognitive function containing Spirulina extract as an active ingredient.
Another object of the present invention is to provide a health functional food for improving dementia or cognitive function comprising Spirulina extract as an active ingredient.
In order to achieve the object of the present invention as described above, the present invention provides a pharmaceutical composition for improving dementia or cognitive function comprising Spirulina extract as an active ingredient.
In one embodiment of the present invention, the spirulina is selected from the group consisting of spirulina ( spirulina) platensis) Spirulina maxima, or (spirulina maxima ).
In one embodiment of the present invention, the spirulina extract is prepared by mixing (a) the dried spirulina powder with ethanol at a ratio of 1: 8 to 1:10 (w / w) At a temperature of 55 to 65 캜 for 6 to 12 hours, and (b) filtering the ultrasound-treated Spirulina extract and concentrating under reduced pressure.
The present invention also provides a health functional food for improving dementia or cognitive function comprising Spirulina extract as an active ingredient.
In one embodiment of the present invention, the spirulina extract is prepared by mixing (a) the dried spirulina powder with ethanol at a ratio of 1: 8 to 1:10 (w / w) At a temperature of 55 to 65 캜 for 6 to 12 hours, and (b) filtering the ultrasound-treated Spirulina extract and concentration under reduced pressure.
The present invention relates to a pharmaceutical composition for improving dementia or cognitive function comprising Spirulina extract as an active ingredient. The Spirulina extract of the present invention has excellent antioxidative activity, has a cognitive function improving effect, And since there is no side effect in the body due to its low toxicity as a natural ingredient, there is an effect that it can be effectively used for the production of new medicines and health functional foods for dementia or cognitive function improvement and treatment.
Fig. 1 shows the result of measuring the antioxidative activity of the spirulina extract of the present invention.
Fig. 2 shows the results of measuring the brain-protective activity of the Spirulina extract of the present invention.
Fig. 3 shows the results of an underwater maze test of the spirulina extract of the present invention.
Figure 4 shows the results of manual avoidance experiments of the Spirulina extract of the present invention.
Hereinafter, the present invention will be described in detail.
All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the relevant field of the present invention unless otherwise defined. Also, preferred methods or samples are described in this specification, but similar or equivalent ones are also included in the scope of the present invention.
The present invention is characterized in that Spirulina extract has improved cognitive function and therapeutic effect.
The inventors of the present invention completed the present invention by confirming that Spirulina extract has such an effect while searching for a therapeutic agent for improving dementia and cognitive function which is stable in the body and has excellent therapeutic effect.
In particular, the present invention shows that Spirulina extract has excellent antioxidative activity, has a high activity to protect neuronal cells, and effectively improves cognitive function through mouse animal models.
Accordingly, the present invention provides a pharmaceutical composition for improving dementia or cognitive function comprising Spirulina extract as an active ingredient.
Spirulina is a blue-green cyanobacterium and has a spiral shape. Its size is 10μ in width and 300 ~ 500μ in length, and each cell can be observed visually. The word spirulina comes from a Latin word meaning spiral or spiral, both of which coexist with the word spiral. Spirulina has been known since the announcement of Spirulina in 1967 at the International Conference on Applied Microorganisms in Spirulina, which is native to Lake Aranggui, near Ethiopia. The new plant is similar to chlorella, but has a much higher protein content, Very good, easy to cultivate, harvest, showing strong alkalinity. Seaweeds are classified into blue, green, red, and brown by primary hue. Spirulina is a kind of teal. Its color is the color emitted by the phycocyanin (blue) of chlorophyll (green) in the cell.
Such spirulina has been known to have atopic prevention effect, is known to have an inhibitory effect on skin aging, and is known to have an effect of improving lipid metabolism, but studies on other physiological activities have not yet been conducted.
In this respect, the present invention has identified a new use of spirulina, and it can be utilized as a material for improving dementia or cognitive function. Examples of the spirulina usable in the present invention include, but are not limited to, spirulina Spirulina It can be platensis) and Spirulina maxima (spirulina maxima).
The spirulina extract of the present invention is prepared by mixing (a) dried spirulina powder with ethanol at a ratio of 1: 8 to 1:10 (w / w), (b) ultrasonic condition at 30 to 120 kHz, Deg.] C for 6 to 12 hours, and (b) filtration of the sonicated Spirulina extract and concentration under reduced pressure.
In addition, the pharmaceutical composition according to the present invention can be prepared using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the active ingredient, that is, the spirulina extract. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, Replenisher, swelling agent, lubricant, lubricant, or flavoring agent.
The spirulina extract of the present invention may be a suitable solvent for obtaining the extract. Any pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used. Examples thereof include, but are not limited to, For example, an alcohol having 1 to 4 carbon atoms such as purified water, methanol, ethanol, propanol, isopropanol, and butanol, acetone, ether, benzene various solvents such as benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination. It is preferable to use ethanol (alcohol), more preferably 70% ethanol.
As the extraction method, any one of a hot water extraction method, a cold extraction method, a reflux cooling extraction method, a solvent extraction method, a steam distillation method, an ultrasonic extraction method, a leaching method and a pressing method can be selected and used. Preferably, Can be used.
The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described effective ingredients for administration.
The pharmaceutical form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added.
In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
Diseases to which the pharmaceutical composition according to the present invention can be applied include dementia. Alzheimer's dementia, cerebrovascular dementia, Pick's disease, Kruszfeld-Jacob disease, dementia caused by head injury, and Parkinson's disease have.
Refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue, animal, or human context contemplated by a researcher, veterinarian, physician, or other clinician, Lt; / RTI > includes an amount that induces relief of symptoms of the disorder. It will be apparent to those skilled in the art that the therapeutically effective dose and the number of administrations of the active ingredient of the present invention will vary depending on the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. In the treatment method of the present invention, in the case of an adult, it is preferable to administer the spirulina extract of the present invention at a dose of 0.01 mg / kg to 250 mg / kg once to several times a day.
In addition, the health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and rings for the purpose of prevention and treatment of diseases related to cognitive dysfunction.
In the present invention, the term " health functional food " refers to foods manufactured and processed using raw materials or ingredients having useful functions in accordance with Law No. 6727 on Health Functional Foods. Or to obtain a beneficial effect in health use such as physiological action.
The health functional foods of the present invention may contain conventional food additives and, unless otherwise specified, whether or not they are suitable as food additives are classified according to the General Rules for Food Additives approved by the Food and Drug Administration, Standards and standards.
Examples of the items listed in the above-mentioned "food additives" include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as persimmon extract, licorice extract, crystalline cellulose, high color pigment and guar gum; L-glutamic acid sodium preparations, noodle-added alkalis, preservative preparations, tar coloring preparations and the like.
For example, a health functional food in the form of tablets may be prepared by granulating a mixture of Spirulina extract, which is an active ingredient of the present invention, with an excipient, a binder, a disintegrant and other additives in a usual manner, Alternatively, the mixture can be directly compression molded. In addition, the health functional food of the tablet form may contain a mating agent or the like if necessary.
The hard capsule of the capsule type health functional food can be prepared by filling a normal hard capsule with a mixture of Spirulina extract, an active ingredient of the present invention, with an additive such as an excipient. The soft capsule is prepared by adding Spirulina extract to excipients such as excipients And filling the mixture with a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.
The ring-shaped health functional food can be prepared by molding a mixture of Spirulina extract, which is an effective ingredient of the present invention, excipient, binder, disintegrant, and the like, according to a conventionally known method and, if necessary, Or the surface may be coated with a material such as starch, talc.
The granular health functional food may be prepared by granulating a mixture of Spirulina extract, an active ingredient of the present invention, an excipient, a binder, a disintegrant, and the like in a granular form by a conventionally known method and, if necessary, adding a flavoring agent, ≪ / RTI >
The health functional food may be a beverage, a meat, a chocolate, a food, a confectionery, a pizza, a ramen, a noodle, a gum, a candy, an ice cream, an alcoholic beverage, a vitamin complex and a health supplement food.
Reference will now be made to the embodiments described hereinafter with respect to characteristic parts of the present invention and manufacturing method thereof. Hereinafter, the present invention will be described in detail with reference to examples. However, these examples are intended to illustrate the present invention in detail, and the scope of the present invention is not limited to these examples.
< Example 1>
Ultrasonically Spirulina Preparation of extract
To obtain the spirulina extract, 100 g of spirulina platensis in the form of powder, which was dried first, was mixed with 70% ethanol at a ratio of 1:10 (W / W), and then ultrasonicated at 80 kHz, Extraction was carried out for 10 hours. After the extraction, the obtained Spirulina ultrasound extract was filtered and concentrated under reduced pressure, and then lyophilized to give a powdery form, followed by the following experiment.
< Experimental Example 1>
Spirulina Determination of antioxidative activity of extract
The antioxidative activity of Spirulina extract obtained in Example 1 was measured. Antioxidant activity was measured by DPPH scavenging activity and ascorbic acid (0.2 mg / mL), a known antioxidant, was used as a positive control.
Spirulina extract and ascorbic acid were mixed with 80 μL and 200 μL of 0.1 mM DPPH, respectively. After incubation at 25 ° C. for 20 minutes, the degree of antioxidation was measured by measuring the absorbance at 525 nm. At this time, the spirulina extract was analyzed by varying the concentrations as shown in Fig.
As a result, as shown in FIG. 1, the antioxidant activity of Spirulina extract was increased in a concentration-dependent manner. As a result, the Spirulina extract of the present invention had a high antioxidative activity.
< Experimental Example 2>
Spirulina Cytotoxicity and neuroprotective activity of extracts
The cytotoxicity of Spirulina extract was measured. MTT reagent was used for cytotoxicity measurement, and HT22 cells, a cell line derived from mouse hippocampus, were used as the cells. HT22 cells were cultured in DMEM supplemented with 10% FBS in a 5% CO 2 incubator at 37 ° C. MTT assays were performed to measure brain cytotoxic activity against glutamate-induced toxicity. HT22 cells were cultured in 48-well plates at a concentration of 5.0 × 10 3 cells / well. After culturing for 23 hours, trolox was treated with Spirulina extract or a positive control. After culturing for 1 hour, 30 μl of 1.8 mM glutamate was treated. After 24 h incubation, medium was removed and MTT assay was performed. OD value was measured at 570 nm using a microplate reader. Brain cell protection activity was expressed as relative protection (%).
As a result, as shown in Fig. 2, it was found that the spirulina extract had an excellent protective activity against brain nerve cells in a concentration-dependent manner.
< Experimental Example 3>
Spirulina Depending on the treatment of the extract Cognitive ability Analysis of improvement effect
The present inventors conducted an underwater labyrinth experiment on animals having an activity of inducing cellular activity of the spirulina extract to improve dementia and cognitive function. As a control group, mouse group treated with Spirulina extract was used as a control group and mouse group not treated with Spirulina extract was used as a control group. At this time, scopolamine-treated group and donepezil-treated group of dementia were used as comparative groups. For each sample, mice were treated with donepezil and spirulina extract for 120 minutes before the start of the experiment using metal oral dosing regimens, and scopolamine to induce
In the present invention, 4 weeks old SPF male ICR mice were used for the underwater maze test. The animals were subjected to adaptation period in the breeding environment for one week after the ingestion, the animals were weighed during the adaptation period, and the selected animals were uniformly distributed to the average weight of each group, The ambient conditions were set to 50 ± 5% in humidity, 10 to 15 times / hr in ventilation, 12 hours in lighting time (7.5 hours in the morning to 7.5 hours in the evening), and 150 to 300 lux in the illumination. The underwater maze test was performed using the EthoVision Maze test system (Noldus Information Technology, Wageningen, Netherlands). When the animal remembers the markers around the water tank and visits the esophagus located in a certain place in the water tank for more than 10 seconds, the escape latency is set to escape latency twice a day Mean escape latency was defined as the mean value. Experiments were carried out twice a day for 4 consecutive days. If the animal was not found within 120 seconds, the animal was placed on the escape pod for 10 seconds. After the experiment, the incubation period was set to 120 seconds.
As a result of the analysis, as shown in Fig. 3, in the case of the group treated with Spirulina extract, the escape latency gradually decreased during the 4 days of the experiment, It has been shown to have a therapeutic effect similar to that of the drug donepezil.
Therefore, the present inventors have found that the spirulina extract of the present invention can be used as a novel medicament for replacing conventional cognitive function or dementia treatment.
< Experimental Example 4>
Spirulina Experimental measurement of passive avoidance of extract
To evaluate the effect of spirulina extract on learning and memory, a manual avoidance test was performed using a manual evasive box (GEMINITM Avoidance System, San Diego Instrument, San Diego, Calif., USA). If you put an animal in a bright room of a manual evasive box divided into a dark room and a bright room, you will go to a dark room and then an electric shock for 2 seconds. After 24 hours of electric shock, when the animal is placed back in a bright room, the electric shock of the dark room is memorized, suppressing the nature of going to the dark room. At this time, the step through latency in the bright room is measured Respectively. The experimental animals used in the experiment were the mice used in Experimental Example 3 above.
As a result, as shown in Fig. 4, the Spirulina extract showed no significant activity in the long-term memory region, and the effect was significant in short-term memory as shown in Fig. Therefore, it was found that the spirulina extract of the present invention can effectively improve scopolamine-induced memory impairment.
The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (5)
The spirulina may be selected from the group consisting of spirulina ( spirulina) platensis) or Spirulina maxima (spirulina maxima) composition, characterized in that.
The Spirulina extract may contain,
(a) The dried spirulina powder is mixed with 50 to 70% ethanol at a ratio of 1: 8 to 1:10 (w / w), and then ultrasonicated at 30 to 120 kHz, After heating for 12 hours,
(b) the extract obtained through filtration and concentration under reduced pressure of the sonicated Spirulina extract.
The Spirulina extract may contain,
(a) The dried spirulina powder is mixed with 50 to 70% ethanol at a ratio of 1: 8 to 1:10 (w / w), and then ultrasonicated at 30 to 120 kHz, After heating for 12 hours,
(b) the extract obtained by filtering the ultrasound-treated spirulina extract and concentrating under reduced pressure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150174170A KR20170067466A (en) | 2015-12-08 | 2015-12-08 | Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150174170A KR20170067466A (en) | 2015-12-08 | 2015-12-08 | Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170067466A true KR20170067466A (en) | 2017-06-16 |
Family
ID=59278672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150174170A KR20170067466A (en) | 2015-12-08 | 2015-12-08 | Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170067466A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102007675B1 (en) * | 2019-03-05 | 2019-08-06 | 한국해양과학기술원 | Method for production of spirulina extracts, pharmaceutical compositions and health functional foods comprising spirulina extracts for improving cognitive ability |
| KR20200061690A (en) * | 2018-11-26 | 2020-06-03 | 서원대학교산학협력단 | Method of preparing spirulina extract having high content of chlorophyll and composition for improving cognitive ability for long term which contains the same |
| KR20200065277A (en) * | 2018-11-30 | 2020-06-09 | 서원대학교산학협력단 | Method of preparing spirulina extract having high content of chlorophyll using fluidized-bed extraction apparatus and spirulina extract prepared by the same |
-
2015
- 2015-12-08 KR KR1020150174170A patent/KR20170067466A/en not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200061690A (en) * | 2018-11-26 | 2020-06-03 | 서원대학교산학협력단 | Method of preparing spirulina extract having high content of chlorophyll and composition for improving cognitive ability for long term which contains the same |
| KR20200065277A (en) * | 2018-11-30 | 2020-06-09 | 서원대학교산학협력단 | Method of preparing spirulina extract having high content of chlorophyll using fluidized-bed extraction apparatus and spirulina extract prepared by the same |
| KR102007675B1 (en) * | 2019-03-05 | 2019-08-06 | 한국해양과학기술원 | Method for production of spirulina extracts, pharmaceutical compositions and health functional foods comprising spirulina extracts for improving cognitive ability |
| WO2020180025A1 (en) * | 2019-03-05 | 2020-09-10 | 한국해양과학기술원 | Method for producing spirulina extract, and spirulina extract-containing pharmaceutical composition and health functional food for improving cognitive ability |
| CN113543793A (en) * | 2019-03-05 | 2021-10-22 | 韩国海洋科学技术院 | Preparation method of spirulina extract, and pharmaceutical composition and health functional food containing spirulina extract for improving cognitive ability |
| JP2022522798A (en) * | 2019-03-05 | 2022-04-20 | コリア インスティチュート オブ オーシャン サイエンス アンド テクノロジー | Method for producing spirulina extract, pharmaceutical composition for improving cognitive function and health functional food containing spirulina extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3193898B1 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| US20220160798A1 (en) | Method for producing spirulina extract, and spirulina extract-containing pharmaceutical composition and health functional food for improving cognitive ability | |
| KR102227186B1 (en) | Composition comprising the extract of Belamcanda chinensis for preventing or treating neuro degenerative disease | |
| KR20170067466A (en) | Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract | |
| KR101934794B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component | |
| KR101033671B1 (en) | Anticancer health foods including Phellinus linteus and vegetable worms | |
| KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
| KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
| KR20200063772A (en) | Composition for anti-inflammation comprising extract of mealworm containing ginsenoside Re | |
| KR101680013B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| CN110691590A (en) | Composition for preventing and/or improving brain dysfunction, containing xanthophyll or its salt and processed product of Trapa plant | |
| JP4371431B2 (en) | Antiallergic composition | |
| KR101509056B1 (en) | Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 | |
| KR102038644B1 (en) | A pharmaceutical composition comprising tetragonia tetragonoides extract for preventing or treating depression | |
| KR20160081189A (en) | Composition comprising an extract of Eisenia bicyclis for preventing and treating Alzheimers disease | |
| KR101559655B1 (en) | Composition comprising myricetin for inhibition of pancreatic lipase | |
| KR20190126565A (en) | A composition for improving, preventing and treating of pain containing oriental medicine herbs oil extract as an active ingredient | |
| KR20130122426A (en) | Novel use of extract of sasangja | |
| KR101398009B1 (en) | Composition for preventing or treating stress or depressive disorder | |
| KR102165845B1 (en) | Composition for improving eye fatigue by blue light | |
| KR102165654B1 (en) | Method of preparing spirulina extract having high content of chlorophyll using fluidized-bed extraction apparatus and spirulina extract prepared by the same | |
| TWI472333B (en) | Oral herbal composition for the treatment of oral candidiasis | |
| KR101662459B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| E902 | Notification of reason for refusal | ||
| WITB | Written withdrawal of application |